{'fraction_non_alphanumeric': 0.02671118530884808, 'fraction_numerical': 0.01335559265442404, 'mean_word_length': 4.965174129353234, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Results of the treatment of paroxysmal atrial fibrillation with ethacizine].

Ethacizine was given to 28 patients with frequent (at least once a week) paroxysms of cardiac fibrillation (PCF), the larger proportion of the patients was those with coronary heart disease. The long-term use of ethacisine was preceded by an acute drug test in which the drug was administered orally in a starting dose of 100 mg to assess its effects on myocardial conduction and contractility. Its positive effect as evidenced by reduction in PCF frequency by 70% per more was seen in 19 (68%) patients. The antiarrhythmic effect of the drug showed up on day 2 after initiation of the therapy. Analysis of the relationship between the drug's positive effect and the changes in the atrial myocardium showed that the most potent effect (up to 80%) was observed in patients with coronary heart disease complicated with PCF in the presence of "combined" changes in the atrial myocardium as compared to "hemodynamic" changes. The authors studied the most common adverse effects resulted from the therapy, the most dangerous of them included abnormal right bundle branch conduction (1 case) and sinoauricular block (1 case).